CRISPR companies team up to defend IP

On Friday, four companies with licenses or sublicenses to the same foundational CRISPR IP from the University of California Berkeley, the University of Vienna and Emmanuelle Charpentier announced a cross-licensing and invention management agreement. CRISPR Therapeutics AG (NASDAQ:CRSP), Caribou Biosciences Inc. (Berkeley, Calif.), Intellia Therapeutics Inc. (NASDAQ:NTLA) and ERS Genomics Ltd. (Dublin, Ireland), have agreed to jointly prosecute, defend and enforce the IP, along with their licensors.

CRISPR Therapeutics, Caribou and Intellia have licenses or sublicenses to the IP for therapeutic applications. ERS Genomics provides non-exclusive licenses to the same IP for non-therapeutic applications (see BioCentury Innovations, Sept. 22)...